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Abstract
Elucidation of new biomarkers and potential drug targets from high-throughput profiling data is a challenging task due to a
limited number of available biological samples and questionable reproducibility of differential changes in cross-dataset
comparisons. In this paper we propose a novel computational approach for drug and biomarkers discovery using
comprehensive analysis of multiple expression profiling datasets. The new method relies on aggregation of individual
profiling experiments combined with leave-one-dataset-out validation approach. Aggregated datasets were studied using
Sub-Network Enrichment Analysis algorithm (SNEA) to find consistent statistically significant key regulators within the
global literature-extracted expression regulation network. These regulators were linked to the consistent differentially
expressed genes. We have applied our approach to several publicly available human muscle gene expression profiling
datasets related to Duchenne muscular dystrophy (DMD). In order to detect both enhanced and repressed processes we
considered up- and down-regulated genes separately. Applying the proposed approach to the regulators search we
discovered the disturbance in the activity of several muscle-related transcription factors (e.g. MYOG and MYOD1), regulators
of inflammation, regeneration, and fibrosis. Almost all SNEA-derived regulators of down-regulated genes (e.g. AMPK, TORC2,
PPARGC1A) correspond to a single common pathway important for fast-to-slow twitch fiber type transition. We hypothesize
that this process can affect the severity of DMD symptoms, making corresponding regulators and downstream genes
valuable candidates for being potential drug targets and exploratory biomarkers.
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Introduction
Microarray-based expression profiling is a widely used, quick and
inexpensive method to obtain information about the specific diseases.
A traditional approach when searching for drug targets or candidate
biomarkers for a specific disease is to look for genes differentially
expressed between the disease and appropriate ‘‘control’’ samples.
Various techniques have been applied to find statistically significant
differentially expressed genes, including classical statistical tests (e.g. t-
test) and those specifically developed for microarray data analysis
(Limma [1], SAM [2], shrinkage T-statistic [3] and other).
To get the deeper understanding of the disease mechanisms, the
functional analysis of differential genes can be performed using a
number of different methods [4]. Typically they rely on Gene
Ontology (GO) – based annotation of genes. Common approach is
to pre-select differentially expressed genes based on differential
fold-change and/or p-value threshold, and find the statistically
enriched GO groups using Fisher’s exact test. More sensitive
approaches are based on gene set enrichment analysis (GSEA
[5,6]) to avoid differential cut-off selection issue.
In addition to Gene Ontology, the protein-protein functional
associations, regulatory or biochemical networks can also be used
as a source of functional protein annotation in enrichment analysis
[6,7,8]. More elaborated classification and functional annotation
methods [9,10] are usually applied to protein-protein networks
only. The potential drawback of this kind of networks for the
analysis of expression data is that they eventually skip the
important transcriptional factors if they are not differentially
expressed themselves. In this paper we used a proprietary
literature-derived gene expression regulation network as a source
of functional protein annotation. This global expression network
consists of direct or indirect effects of a network node (protein) on
expression of other genes [11]. Unlike conventional GSEA [5,6],
which uses predefined collection of gene sets, Sub-Network
Enrichment Analysis (SNEA) algorithm, implemented in Pathway
StudioH software [11], constructs comprehensive collection of gene
sets from ResNet, a global literature-extracted protein-protein
regulation network. The gene sets are constructed for each
individual network node (‘‘seed’’) and consist of all its downstream
expression targets only (star-like subnetworks).
The central idea of SNEA approach is that if the downstream
expression targets of a ‘‘seed’’ are enriched with differentially
expressed genes, then the ‘‘seed’’ is likely to be one of the key
regulators of the differential expression changes, e.g. a transcrip-
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an upstream member of signaling pathway [12]. This literature-
driven approach connects differentially expressed genes to major
implicated pathways and key expression regulators. In contrast to
other methods that utilize the same idea of finding upstream
network regulators using expression data [13,14], SNEA allows
identification of any potentially important protein (not obligatory a
transcriptional factor) leading to the observed expression changes,
even if its own expression doesn’t change. It becomes possible
because of the usage of ResNet database where all relations are
taken from the literature only. Hence, there is no restriction on the
protein type that can be considered as potential ‘‘seed’’, provided
that it is reported to influence each individual downstream gene
expression.
We have applied this approach to study Duchenne muscular
dystrophy (DMD) using publicly available gene expression profile
datasets and identified a set of potential regulators and
downstream biomarkers of DMD progression and severity.
Duchenne muscular dystrophy is an X-linked recessive
muscular disorder, caused by mutations in the dystrophin gene
(DMD) [15–17]. Affecting about 1:3500 newborn males, it is the
most common form of muscular dystrophies and the most
common sex linked disease in males [18]. The underlying genetic
cause of DMD is the presence of a variety of DMD gene mutations
that result in dystrophin reduction/absence in skeletal muscle [17].
Lack of dystrophin has multiple unfavorable consequences to a
muscle fiber (reviewed in [19]), leading to apoptosis or necrosis
with subsequent inflammation and fibrosis at the site of damage.
The process of muscle regeneration is also activated, but, in
humans, with the course of the disease the repair capacity declines
and becomes insufficient [20]. Muscle tissue is replaced with
adipose and fibrous connective tissue [21].
The average life expectancy of DMD patients varies from late
teens to early thirties, and can be improved by respiratory support
[22,23] and drug therapy [24]. Currently, there is no cure for
DMD, but some treatments targeting the secondary consequences
of dystrophin deficiency, such as muscle damage, necrosis,
apoptosis and failure of regeneration, are already available for
patients. Glucocorticoids, such as prednisone and deflazacort, are
widely used to alleviate some of the disease’s symptoms [25].
Several tests are used in diagnostics of DMD, including
measurement of physical parameters, serum level of creatine
kinase, genetic testing for DMD mutations and muscle biopsy to
confirm the reduction in dystrophin content. More accurate,
preferably non-invasive and biologically explainable markers are
needed to predict prognosis, estimate disease’s severity and
progression. Also new biomarkers are required in treatment and
clinical trials for DMD, where they can be used to monitor drug
efficiency and choose optimal drug dose.
In order to identify potential drug targets along with
corresponding biomarkers, we have searched for the consistent
SNEA regulators and their downstream expression targets using
publicly available differential gene expression profiles and
literature-extracted expression regulation network from muscle
biopsies of patients with DMD. Suggested workflow implies
aggregation of the data from multiple datasets and elucidation of
common mechanisms that underlie differential expression. Study-
ing these mechanisms from the prospective of searching for new
drug targets can provide valuable insights in both biological and
medical research.
Results/Discussion
Workflow
The overall analysis workflow is presented in Figure 1. Five
NCBI GEO DMD-related microarray expression profiles from
muscle biopsies were aggregated according to the procedure
described in Methods. To ensure robustness of our analysis we
constructed five leave-one-out datasets each time aggregating four
distinct experiments and omitting one out of total five available
experiments. We also constructed single large dataset (referred to
as ‘‘aggregated dataset’’), where all five available microarray
experiments were aggregated. Additional dataset (referred to as
‘‘reference dataset’’) was constructed on the base of published
meta-analysis [26], see Methods.
We performed SNEA with default parameters for each of the six
datasets (five leave-one-out datasets plus aggregated dataset) and
obtained six lists of 100 significant regulators. Regulators common
for all six datasets were combined with regulators obtained by
SNEA of reference dataset. This resulted in the list of 76 unique
regulators, which can be viewed as potential drug targets. We also
performed permutation test to ensure that this overlap is significant.
Next, we turned to selection of differentially expressed genes.
For each of the 6 datasets (five leave-one-out datasets plus
aggregated dataset) we performed gene ranking using combination
of different methods (see Methods section). Then we identified
genes which were present in top-500 lists for all six datasets. Out of
all these consistently differentially changed genes, we have selected
only those which were expression targets of selected consistent
significant regulators. This produced a list of 140 candidate genes
(105 over- and 35 under-expressed). These genes (potential
biomarkers) have been sorted using the combination of expression
rank in the aggregated dataset and the number of significant
regulators as a score (see Methods section). We also manually
evaluated top-20 up-regulated genes and top-10 down-regulated
genes in respect to the supporting evidences from the available
literature.
All analytical procedures were applied separately to over-
expressed genes and under-expressed genes to look individually at
processes and pathways activated and repressed in DMD.
Significant regulators identified by SNEA
The significant regulators of up- and down- regulated
differentially expressed genes from six datasets were cross-
Author Summary
Comparison of gene expression in diseased and normal
tissue is a powerful tool of studying processes involved in
pathogenesis and searching for potential drug targets and
biomarkers of the disease’s progression and treatment
outcome. We have developed a novel approach for
systematic knowledge-driven analysis of gene expression
profiling data, which can suggest the underlying cause of
the observed differential expression by identifying which
expression regulators might be involved. These regulators
can not only be the promising subjects of further
investigation, but also potential drug targets, as normal-
ization of their activity might alleviate some of the
disease’s symptoms. The targets downstream of suggested
regulators can be proposed as exploratory biomarkers in
disease treatment and prognosis. We used our approach
to analyze public gene expression datasets of Duchenne
muscular dystrophy – a progressive inherited disease in
males. Some of the regulators and biomarkers that we
found were already investigated in the context of DMD,
while some of them were not yet studied and may be of
interest for biological and clinical studies.
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further analysis. They were combined with regulators obtained
from the SNEA of the reference dataset to produce the final list of
76 unique significant regulators shown in Table 1 below. More
information about these regulators can be found in Table S1.
Regulators of up-regulated genes. Overall, regulators of
up-regulated genes correspond to the major processes that take
place in dystrophic muscle, such as inflammation, fibrosis and
muscle regeneration. Among regulators of up-regulated genes we
can separate members of several known signaling cascades:
NFKB, angiotensin signaling (AGT, functional class angiotensin
II receptor, chymase (CMA1)), TGF signaling (functional class
TGF family, TGFB1, TGFB2, BMP2, functional class SMAD,
SMAD7), and interferon gamma signaling (IFNG, STAT1, IRF1),
suggesting that these pathways may be disturbed in dystrophin-
deficient muscle.
An indirect proof of our approach is the fact that some of our
regulators were shown to contribute to the disease progression in
DMD patients and animal models of DMD, such as mice (mdx)
and golden retriever (GRMD). Mdx mouse is the most widely
used model of DMD, although the pathology is much milder in
these animals. GRMD is clinically more similar to an actual
disease, due to the size of animals and severity of symptoms
[27,28]. According to PubMed at least 17 out of 37 SNEA-
derived regulators of up-regulated genes are related to DMD in
human or animal models. Moreover, several regulators were
already tested as potential drug targets in mdx mice with
generally positive outcome, suggesting that the rest of SNEA-
proposed regulators also might be of interest. For example, there
is strong evidence of NFKB pathway involvement in DMD
progression [29,30]. Blocking of NFKB was suggested as a
potential therapy against DMD, as it stimulates regeneration and
decreases necrosis in mdx mice [31,32].
It was also shown, that members of angiotensin system are
overexpressed in dystrophic muscles and that they may play role
in subsequent activation of TGFB signaling cascade [33],
observed in DMD patients [34,35]. TGFB plays role in fibrosis
and also in impaired muscular regeneration through inhibition of
myogenic factors MYOG and MEF2D, and repression of
myotubes formation [36]. Noteworthy, we found that another
member of TGFB family, TGFBR2, was a consistently
differentially expressed gene. Angiotensin II receptor and
angiotensin converting enzyme were widely studied as drug
targets in the context of DMD [37–39].
Role of TGFB1 was shown in humans, mdx mice and GRMD
[40]. Recently TGFB1 was tested as a potential drug target and it
was shown, that its inhibitors protect muscles of mdx mice from
exercise induced damage and decrease fibrosis [41].
Activation of TGFB may by turn cause up-regulation of
connective tissue growth factor (CTGF) [42] and vice versa [43],
promoting fibrotic changes in dystrophin-deficient skeletal and
cardiac muscles [40,42,43].
Figure 1. Overall workflow of the analysis. See corresponding section for detailed description.
doi:10.1371/journal.pcbi.1002365.g001
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dystrophin deficiency, what can be reverted by HDAC inhibitors
(reviewed in [44]
Activation of IFNG pathway may contribute to muscular
regeneration, fibrosis, inflammation and antigen presentation [45–
47]. The involvement of IFNG signaling in DMD was demonstrat-
ed in several publications: IFNG production was shown to be
increasedinlymph nodes[48] aswell astranscriptional activityofits
downstream target STAT1indiaphragmmusclesofmdxmice [49].
The level of another SNEA-derived regulator, FGF2, is also
elevated both in mdx mice [50] and in serum of Duchenne
patients [51]. FGF2 is involved in skeletal satellite cells activation
and proliferation [52], and its blood level correlates with muscular
regeneration in DMD patients and thereby it can be used as a
biomarker of this process [53].
The role of transcription factor ZEB1 (zinc finger E-box-
binding homeobox 1) in DMD hasn’t yet been described in
literature. ZEB1 inhibits muscular differentiation by blocking
transcriptional activity of myogenic transcription factors, such as
MEF2C [54]. Interestingly MEF2C is a SNEA-derived regulator
of down-regulated genes. In addition ZEB1 synergize with SMAD
and can regulate TGFB signaling [55]. As both myogenesis and
TGFB signaling are affected in DMD, studying ZEB1 in the
context of DMD may look promising.
Being one of the top up-regulated genes in aggregated dataset
(rank 7, log-ratio 2.11) RUNX1 was also found as a significant
regulator of up-regulated genes from reference dataset. To our
knowledge there are no publications, establishing linkage between
RUNX1 and DMD. RUNX1 may be relevant for the disease, as it
is strongly induced in denervated muscles, where its proposed role
is to protect disused myofibers from disorganization, autophagy
and muscle wasting [56].
Taking into the account the strong literature support of
described regulators significance we can suggest other SNEA-
derived regulators as well as their functional protein partners for
further investigations for the role of potential drug targets.
Regulators of down-regulated genes. Up-regulation of
inflammation-related genes is the most prominent expression
pattern in dystrophin-deficient muscle. Separation of down-
regulated genes allows independent analysis of the processes
potentially repressed under this condition.
Among proteins that regulate expression of negatively regulated
genes there is a group of factors working synergistically in a
number of processes crucial to a muscular physiology, e.g. muscle
remodeling and myogenesis (see Figure 2, representing some of the
relations between regulators of down-regulated genes).
In response to the changing environmental and physiological
demands myofibers can significantly alter the gene expression to
adapt to the current needs. It happens through the switch between
slow and fast fiber types that differ in their size, metabolism and
contractile function, in a process of muscle remodeling. Slow-
twitch fibers are rich in mitochondria content, have oxidative
metabolism and are resistant to fatigue. Fast-twitch fibers are
glycolytic and function in quick contractions (reviewed in [57]).
DMD preferentially affects fast-twitch myofibers, while slow-twitch
fibers show less damage [58]. One of the proposed reasons of
higher slow fibers’ survivability is up-regulation of utrophin, a
dystrophin homolog that can function as a partial replacement for
dystrophin [59].
Several factors that were obtained by SNEA of down-regulated
genes play role in muscle remodeling (e.g. PPARGC1A, PPARD,
AMPK, TORC2, MEF2C, MYOG, MYOD). They coordinate
mitochondria biogenesis, metabolic and transcriptional changes
that are necessary for transition to a slow-twitch muscle type.
Table 1. Consistent regulators of differentially expressed genes plus regulators from SNEA of reference dataset.
Function Regulation Regulators
Transcription factors positive, negative AML1-ETO, CCAAT factors, CIITA, CTCF, ESRRA, FOXI1, ING4,
MEF2C, MYOD1, MYOG, NF-kB, NR1H2, NR1H4, NR4A2,
PPARD, PPARGC1A, RUNX1, RUNX2, SCXA, SMAD, SMAD7,
SREBF1, SREBF2, STAT1, TWIST1, ZEB1, ZFHX3
Cytokines and cytokines receptors positive, negative ADIPOQ, BMP2, CSF1, CSH1, CTGF, GCG, GH1, IFNG, IL13, IL4,
IL6, IL6R, INS, LEP, PTH, TGF family, TGFB1, TGFB2, TNFRSF11B
Growth factors positive AGT, BMP2, CSF1, CTGF, FGF2, GF, IL4, IL6, TGF family, TGFB1,
TGFB2
Hormones positive, negative ADIPOQ, AGT, CSH1, GCG, GH1, INS, LEP, PTH
MAPK positive MAPK, MAPK3
Extracellular matrix positive collagen type I, vitronectin
Inflammation and immune response positive allergen, CAMP, CCL2, CCR7, CIITA, CMA1, CXCL2, IFNG, IL13,
IL4, IL6, IL6R, IRF1, NF-kB, STAT1, TGF family, TGFB1, TGFB2,
TNFRSF11B, ZEB1
Regulation of metabolic processes negative ADIPOQ, ADRB3, AMPK, GCG, INS, LEP, NR1H2, PPARD,
PPARGC1A, PRKAA2, SREBF1, SREBF2, TORC2, UCP2
TGFB-SMAD pathway positive BMP2, SMAD, SMAD7, TGF family, TGFB1, TGFB2
Muscle-specific factors negative MEF2C, muscle fiber, MYOD1, MYOG
Cell cycle positive CDKN1B, CTCF, ING4, SCXA
IFNG signaling positive IFNG, IRF1, STAT1
Renin-angiotensin system positive AGT, angiotensin II receptor
Chromatin modification positive, negative HDAC1, histone deacetylase inhibitor
Other positive alkaline phosphohydrolase, GJA1, LPL, MIRN29C, RHOA
doi:10.1371/journal.pcbi.1002365.t001
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were already studied in the context of DMD. It was known that
activation of PPARGC1A and PPARD by over-expression or
treatment with agonists ameliorates disease’s symptoms in mdx
mice by promoting slow fibers formation, up-regulation of
utrophin and enhancing neuromuscular junction program
[61,62]. The role of PPARGC1A was also demonstrated in
GRMD, where it was shown that PPARGC1A along with its
targets is dramatically reduced [63]. Recently the role of another
regulator predicted by our SNEA analysis AMPK, was also
confirmed in mdx mice. It was shown that activation of AMPK by
its agonist, AICAR, enhanced oxidative capacity, elicited fast-to-
slow fiber type transition, up-regulated utrophin expression and
increased sarcolemmal integrity [64].
AMPK, PPARGC1A, PPARD as well as other factors
important for fast-to-slow twitch fiber transition activate in
response to exercise, therefore a group of compounds, simulating
the effect of physical exercise, called exercise mimetics, can be
suggested as potential drugs to be tested in mdx mice. Some
exercise mimetics were already successfully tried in mdx mice (e.g.
GW1516, AICAR, resveratrol [62,64,65]). Some of the other
compounds known to stimulate the respective regulators can also
be suggested to improve symptoms in dystrophin deficiencies, e.g.
metformin, acadesine, phenormine, berberine (AMPK stimula-
tors), bezafibrate and GW0742 (PPARD stimulator), pioglitazone
and forskolin (PPARGC1A stimulator), SRT1720 (a more effective
stimulator of SIRT1, than resveratrol).
Interestingly, prednisone, a glucocorticoid that is used in the
therapy of DMD has an opposite effect on muscle fiber type,
decreasing the number of slow-twitch fibers [50].
Another group of significant regulators, such as TORC2 and
UCP2, have not yet been linked to Duchenne muscular dystrophy,
but they are known to regulate mitochondrial biogenesis, which
takes place during muscle remodeling (reviewed in [66,67]). We
can hypothesize, that mitochondria biogenesis is repressed in
dystrophic muscle, as 34 out of 191 consistently down regulated
differentially expressed genes are expressed in mitochondria (e.g. 6
NADH dehydrogenase subunits, 4 mitochondrial ribosomal
proteins, components of respiratory chain and tricarboxylic acids
cycle).
All above-mentioned factors work synergistically during forma-
tion of a slow-twitch myofiber. AMPK activates and up-regulates
PPARGC1A [68,69] and attenuates the gluconeogenic program
by blocking TORC2 nuclear accumulation [70,71]. TORC2 is
also able to promote mitochondrial biogenesis and enhance
oxidative capacity in muscle cells by stimulating PPARGC1A
transcription and up-regulation of ESRRA [67], transcription
factor known to be involved in mitochondrial biogenesis and
Figure 2. Regulators of down-regulated genes. Most of SNEA-derived regulators of down-regulated genes regulate the processes related to
myotube formation, fast-to-slow fiber type switch (including changes in myofiber composition, mitochondria content and insulin sensitivity) and
metabolic changes in DMD affected muscles. Relations are described in text. Catalytic subunit of AMPK, PRKAA2, is shown next to AMPK. Functional
class - class of proteins, such as enzyme families. Complex - a group of two or more proteins linked by non-covalent protein-protein interactions.
Expression - protein members of one class regulate expression of proteins in another class. DirectRegulation - protein members of one class bind and
regulate proteins in another class. Regulation - protein members of one class indirectly regulate proteins in another class. ProteinModification -
protein members of the regulator class phosphorylate or otherwise modify proteins in the target class. PromoterBinding - protein members of one
class bind promoters of genes encoding proteins in another class.
doi:10.1371/journal.pcbi.1002365.g002
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PPARGC1A [73]. Myogenic factors MYOG, MYOD and
MEF2C were shown to bind PPARGC1A promoter at the late
stages of muscle differentiation [74,75].
The process of muscle remodeling is connected to the change in
insulin sensitivity. It was shown, that fast-twitch myofibers are
more insulin resistant, while slow-twitch myofibers are more
insulin sensitive [76]. Interestingly insulin is one of the significant
regulators of down-regulated genes derived from analysis of
reference dataset, as well as glucagon and adipokines, leptin and
adiponectin. The presence of adipokines among regulators of gene
expression in DMD can be explained by metabolic and
histological changes in dystrophic muscle.
Three myogenic factors: MYOD, MYOG and MEF2C, co-
acting during muscle development ([77], reviewed in [78]) were
shown to be significant regulators of down-regulated genes in
aggregated dataset. Many of the aspects of their involvement in
DMD have been already studied, and our results just confirm their
importance in DMD pathogenesis. For example, lack of a master
regulator of skeletal muscle gene expression program MyoD was
shown to result in a significant increase in myopathy’s severity and
premature death in mdx mice due to the decreased regeneration
ability [79]. MyoD impaired activity in dystrophin-deficient
muscle can be caused by activation of NFkB and IFNG pathways
that result in MyoD destabilization [80]. Deletion of another
myogenic factor, MYOG, on the contrary benefits mdx mice by
improving fatigue resistance [81]. Both MYOG and MEF2C are
regulated by MYOD. Interestingly, one of the regulators of down-
regulated genes is transcription factor CTCF, found recently to be
a modulator of MyoD and MyoG activity during myogenesis [82].
HDAC1 is also involved in regulation of myogenic program by
blocking MYOD-mediated transcription [83].
As the set of described regulators reflects the impairment of the
same group of processes and 6 of 15 regulators were already
mentioned in the context of DMD and even tested as drug targets,
we can suggest, that the others, such as TORC2, can also be
considered from this point of view.
Selection of differentially expressed genes consistent
between 5 datasets
We have selected genes, which were consistently differentially
expressed in six datasets (one aggregated dataset and five leave-
one-out datasets). The fold-change threshold was established by
analyzing fraction of genes present in all six top-k rankings for
varying k, Figure 3. As can be seen, fraction of common genes in
top-k rankings for different types of gene expression reaches a
plateau for k roughly equal to 500. This means, that adding more
genes will not increase percentage of overlap between different
gene rankings. Hence we limited our analysis to top-500
differentially expressed genes for different types of regulation.
The percentage of consistent genes in top-k of all datasets is about
40% (Figure 3). It means that analysis of differentially expressed
Figure 3. Fraction of common genes in top-k rankings for different types of gene expression. For each of six datasets and for each type
of regulation gene ranking procedure was performed and overlap between six top-k lists was calculated. Fraction of common genes in top-k reaches
saturation for k roughly equal to 500, hence adding more genes will not increase overlap between six rankings.
doi:10.1371/journal.pcbi.1002365.g003
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positives. To increase reproducibility of obtained results we
focused on the genes, presented in all six top-500 rankings.
From the top 500 up-regulated genes in aggregated dataset we
have selected 240 genes also present among top 500 up-regulated in
all 5 leave-one-out datasets. Similarly, from the top 500 down-
regulated genes in aggregated dataset we have selected 191 genes also
present among top 500 down-regulated in all 5 leave-one-out
datasets. These two lists were combined into a single list of 431
consistently up/down regulated differential genes. We performed
Fisher exact test to find significantly enriched categories from Gene
Ontology,correspondingtobiologicalprocesses.Results,presentedin
Table 2, in general reflect known changes that take place in affected
muscles: up-regulated genes are commonly associated with inflam-
mation and immune response, apoptosis and wound healing; down-
regulated genes – with metabolic processes and muscle contraction.
Genes were further analyzed in order to evaluate their quality as
biomarkers. A promising biomarker should be easily detected and
correspond to a DMD-related process (e.g. muscle biology,
fibrosis, inflammation) or DMD-related condition (e.g. dilated
cardiomyopathy). We used a proprietary Ariadne DiseasesFX
Database, which contains literature-extracted information about
various types of relations between genes and diseases as well as
data on presence of gene products in biofluids and among secreted
proteins. We also made use of Ariadne ResNet 7 and Muscle
Biology Gene Ontology, see Methods. Associations between 431
consistently up/down regulated genes and DMD-related processes
and conditions are depicted in Table S2.
Consistent differentially expressed genes downstream
from significant regulators
Out of 431 consistently changed genes, we have selected only those
which are expression targets of significant regulators, selected using
the above procedure. This produced a list of 140 candidate genes (35
down-regulated, 105 up-regulated) that have been finally sorted using
combination of rank in aggregated dataset and number of significant
regulators (see Methods). Most of them correspond to the processes of
development and regeneration, immune response, response to
glucocorticoids, hypoxia and extracellular matrix organization.
Top-ranked 20 positive and 10 negative genes have been
individually analyzed using biological information available from
scientific literature (PubMed). Mainly they are connected to
fibrosis, inflammation, energy metabolism and other processes
known to be affected in DMD. It was found that 12 out of these 30
were previously reported as related to muscle processes/disorders,
the fact that can be considered as a proof of concept, providing the
possibility to suggest new possible biomarker candidates on the
base of suggested procedure.
In summary, this study demonstrates the possibility to decipher
regulatory mechanisms of the specific disease (Duchenne dystro-
phy here) along with corresponding exploratory biomarkers on the
base of multiple microarray data meta-analysis only. A lot of
predicted expressional regulators are known to be involved in
DMD, suggesting that others will also be verified hereafter. This
means that all of the proposed regulators can be considered for
further drug discovery, whereas their consistently differentially
expressed downstream genes can serve as exploratory biomarkers
with implicated mechanistic models.
Methods
Source data
All available microarray datasets of human DMD with more
than 10 samples (total 5 datasets, see Table 3) were downloaded
from NCBI GEO database [http://www.ncbi.nlm.nih.gov/geo/].
For each probeset intensity values were log-transformed and
normalized to zero mean and unit variance. Missing data were
imputed using K-nearest neighbor method with k=10.
Reference dataset
We have also utilized data presented in [26], where the lists of up-
and down-regulated genes were extracted from research papers,
related to skeletal muscle development and pathologies. We limited
this dataset to studies of DMD or mdx mice resulting in total 2227
geneswhichwerereported tobedifferentiallyexpressedinatleastin
one paper prior to December 2005. For these genes we generated a
pseudo-expression dataset for further analysis similar to the
standard microarray experiment. If gene was reported to be up-
regulated, the gene was assigned a positive value equal to
corresponding number of supporting studies; if gene was reported
to be down-regulated, the assigned value was negative.
Dataset aggregation (gene ranking)
To combine the data from different datasets, we performed the
following aggregation procedure. For each probeset we calculated
Table 2. Gene Ontology groups enriched by consistent
differentially expressed genes.
GO Process
Number of
genes p-value
Up-regulated genes
cell adhesion 23 1.92E-09
immune response 20 6.8E-08
proteolysis 13 0.00193
apoptosis 12 0.001376
negative regulation of cell proliferation 10 0.00025
inflammatory response 10 0.000111
cell motion 10 3.76E-08
heart development 9 1.08E-05
skeletal system development 9 2.48E-06
wound healing 9 3.45E-09
Down-regulated genes
carbohydrate metabolic process 16 2.94E-11
metabolic process 14 0.000619
oxidation reduction 12 0.00102
modification-dependent protein catabolic
process
11 0.000211
glycogen metabolic process 9 2.16E-12
muscle contraction 8 1.01E-07
response to hypoxia 7 0.000119
electron transport chain 7 6.87E-06
nervous system development 6 0.040331
response to drug 6 0.00847
Biological processes from Gene Ontology associated with consistently
differentially expressed genes were found by applying ‘‘Find groups enriched
with selected entities’’ tool embedded in Ariadne Pathway Studio to the list of
431 genes. Resulting significant (p-value,0.05) biological processes were
sorted by number of genes involved in a process. Top 10 processes are shown.
doi:10.1371/journal.pcbi.1002365.t002
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sum test and area under ROC curve. If gene on a chip was
represented by two or more probesets, we selected the probeset
with the least p-value for Wilcoxon rank sum test. We also
calculated several other statistics, using popular methods designed
specifically for microarray data: limma, SAM and shrinkage T-
statistic. Limma, Linear Models for Microarrays [1,84], is based
on a Bayesian hierarchical model for posterior odds of differential
expression. SAM, Significance Analysis of Microarrays, was
proposed in [2]. Shrinkage T-statistic stabilizes the variances in
the denominator via a James-Stein approach [3].
Finally, we have combined the results from different experi-
ments to generate the single ‘‘differential’’ rank for each gene.
Separate gene rankings were obtained for nine measures: log-ratio,
Welch’s t-statistic and corresponding p-value, Wilcoxon’s W-
statistic and corresponding p-value, AUC, limma, SAM and
shrinkage T-statistic. We used Fisher’s method to combine p-
values of the same type [85]; values of other statistics were
averaged for each gene. The final gene rank R was calculated as
mean of the ranks from all methods. Each gene was also assigned a
single differential log ratio value calculated as an average
differential log-ratio from 5 original gene expression datasets.
In order to ensure reproducibility of obtained results, we
performed a procedure, analogous to leave-one-out cross-valida-
tion: we constructed additional datasets each time aggregating 4
distinct microarray experiments out of total 5 available experi-
ments. Thus we obtained 5 leave-one-out datasets where each
microarray experiment was omitted. We also built one large
dataset, where all 5 available microarray experiments were
aggregated. All subsequent analyses were performed for resultant
6 datasets and the results were cross-validated as further described.
Sub-Network Enrichment Analysis
For functional analysis of high-throughput data on the level of
potential regulators we used Sub-Network Enrichment Analysis
(SNEA) algorithm, implemented in Pathway Studio software [11].
SNEA is a variation of gene set enrichment analysis algorithm,
but unlike GSEA [5,6] that uses predefined gene sets, SNEA
utilized sub-networks to construct gene sets on the go. Here, each
subnetwork consists of a node (mainly protein or class of proteins –
‘‘functional class’’) in ResNet and all its expression downstream
targets which are automatically derived from the literature. Global
expression network includes direct (i.e. transcriptional factor A1 is
reported in the literature to regulate specific gene B1) and indirect
(i.e. growth factor A2, that can activate specific signaling pathway
results to the change of downstream gene B2 expression) relations
Ai-.Bi. For each subnetwork seed SNEA considers all its
expression targets as a gene set that is used for the classical GSEA
(Mann-Whitney or Kolmogorov-Smirnov statistical tests).
Thus, SNEA determines the activity of expression regulators
based on the differential expression of its targets and favors (assigns
lower p-value) those of them which have more significant
expression changes downstream.
We performed the SNEA in Pathway Studio with the default
parameters: Sub-Network type: gene expression, Mann-Whitney
test, p-value,0.05, number of regulators ,100 for all log-ratio
values (DMD vs. control) from the 6 aggregated datasets. The
consistency of default parameters has been tested using 10
permutation tests. It has been shown, that the rate of significant
SNEA seeds accidentally found in SNEA results applied to
randomized experiment is less than 5%, which is in agreement
with default p-value cutoff 0.05. For the reference dataset we ran
SNEA with the same parameters using number of studies which
reported gene to be differentially expressed. All enrichment
algorithms were applied separately to over-expressed and under-
expressed genes.
Final gene sorting
The final sorting of the differentially expressed genes have been
done using the following score
Score genei ðÞ ~N   abs logratio for genei ðÞ =R
where N – number of significant regulators upstream of the i-th
gene and R –gene rank in aggregated dataset resulted from
expression data analysis only.
Software and databases
Most computations were done using R [http://www.r-project.
org/] and BioConductor [http://www.bioconductor.org/]. Val-
ues of limma, SAM and shrinkage T-statistic were computed using
GeneSelector package [86].
Sub-Network Enrichment Analysis was performed using
Pathway Studio 7.1 from Ariadne Genomics along with ResNet
7, database storing literature-derived network of biological
relations [http://www.ariadnegenomics.com/]. Proprietary Ari-
adne DiseasesFX database was used for evaluation of gene quality
as disease biomarker [Table S2], and ChemEffect [12] was used
for studying drugs, related to the regulators of interest.
Muscle Biology Gene Ontology [http://wiki.geneontology.org/
index.php/Genes_Involved_in_Muscle_Biology] was used to se-
lect genes associated with muscle-related processes.
Supporting Information
Table S1 Consistent regulators of differentially ex-
pressed genes. Table contains description of SNEA-derived
regulators (name, description, Entrez Gene ID); information
whether regulator affects expression of up- or down-regulated
genes, number and names of datasets, where regulator was found as
a significant one; number of downstream consistently differentially
Table 3. GEO datasets used for the meta-analysis.
GEO ID Platform Description Source Reference
GDS 214 custom Affymetrix 4 healthy, 26 DMD Muscle [87]
GDS 563 Affymmetrix U95A 11 healthy, 12 DMD Quadriceps Muscle [88]
GDS 1956 Affymetrix U133A 18 healthy, 10 DMD Muscle [84]
GDS 2855 Affymetrix U133B 20 healthy, 10 DMD Muscle [84]
GDS 3027 Affymetrix U133A 14 healthy, 23 DMD Quadriceps Muscle [89]
doi:10.1371/journal.pcbi.1002365.t003
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datasets; information whether regulator was already mentioned in
PubMed publications related to DMD.
(XLSX)
Table S2 Consistently differentially expressed genes.
Table contains a list and description of consistently differentially
expressed genes from aggregated dataset (description, Entrez Gene
ID), their rank and log ratio, number of consistent regulators (see
Table S1), regulating gene expression, association with DMD-
related processes and conditions (from Ariadne DiseaseFX and
ResNet7, Gene Ontology, Muscle Biology Gene Ontology).
(XLSX)
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